1. Home
  2. HOWL vs SKYE Comparison

HOWL vs SKYE Comparison

Compare HOWL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • SKYE
  • Stock Information
  • Founded
  • HOWL 2017
  • SKYE 2012
  • Country
  • HOWL United States
  • SKYE United States
  • Employees
  • HOWL N/A
  • SKYE N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • SKYE Health Care
  • Exchange
  • HOWL Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • HOWL 87.4M
  • SKYE 80.7M
  • IPO Year
  • HOWL 2021
  • SKYE N/A
  • Fundamental
  • Price
  • HOWL $1.36
  • SKYE $3.14
  • Analyst Decision
  • HOWL Strong Buy
  • SKYE Buy
  • Analyst Count
  • HOWL 2
  • SKYE 6
  • Target Price
  • HOWL $9.50
  • SKYE $18.67
  • AVG Volume (30 Days)
  • HOWL 263.3K
  • SKYE 178.7K
  • Earning Date
  • HOWL 03-06-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • HOWL N/A
  • SKYE N/A
  • EPS Growth
  • HOWL N/A
  • SKYE N/A
  • EPS
  • HOWL N/A
  • SKYE N/A
  • Revenue
  • HOWL $3,386,000.00
  • SKYE N/A
  • Revenue This Year
  • HOWL N/A
  • SKYE N/A
  • Revenue Next Year
  • HOWL $34.17
  • SKYE N/A
  • P/E Ratio
  • HOWL N/A
  • SKYE N/A
  • Revenue Growth
  • HOWL N/A
  • SKYE N/A
  • 52 Week Low
  • HOWL $1.26
  • SKYE $2.31
  • 52 Week High
  • HOWL $8.19
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 41.40
  • SKYE 52.82
  • Support Level
  • HOWL $1.26
  • SKYE $2.70
  • Resistance Level
  • HOWL $1.45
  • SKYE $3.29
  • Average True Range (ATR)
  • HOWL 0.09
  • SKYE 0.45
  • MACD
  • HOWL 0.02
  • SKYE 0.05
  • Stochastic Oscillator
  • HOWL 45.45
  • SKYE 41.27

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: